Atomi Financial Group Inc. Grows Stock Holdings in Organon & Co. (NYSE:OGN)

Atomi Financial Group Inc. lifted its position in Organon & Co. (NYSE:OGNFree Report) by 26.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 42,034 shares of the company’s stock after buying an additional 8,811 shares during the quarter. Atomi Financial Group Inc.’s holdings in Organon & Co. were worth $804,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV grew its position in Organon & Co. by 1.8% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock valued at $674,000 after acquiring an additional 546 shares in the last quarter. Ballentine Partners LLC increased its stake in Organon & Co. by 3.0% during the 2nd quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock worth $395,000 after buying an additional 552 shares during the period. Bill Few Associates Inc. lifted its holdings in Organon & Co. by 5.4% during the 2nd quarter. Bill Few Associates Inc. now owns 12,218 shares of the company’s stock worth $253,000 after buying an additional 621 shares in the last quarter. GAMMA Investing LLC boosted its position in Organon & Co. by 19.2% in the 2nd quarter. GAMMA Investing LLC now owns 4,036 shares of the company’s stock valued at $84,000 after buying an additional 649 shares during the period. Finally, Benedetti & Gucer Inc. grew its stake in shares of Organon & Co. by 3.4% in the first quarter. Benedetti & Gucer Inc. now owns 20,245 shares of the company’s stock worth $381,000 after acquiring an additional 670 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Performance

NYSE:OGN opened at $18.03 on Thursday. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $23.10. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17. The firm has a market capitalization of $4.64 billion, a PE ratio of 4.41, a price-to-earnings-growth ratio of 0.82 and a beta of 0.84. The business’s fifty day moving average price is $20.28 and its 200 day moving average price is $20.16.

Organon & Co. (NYSE:OGNGet Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.04. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The business had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.61 billion. During the same quarter in the prior year, the business posted $1.31 EPS. The business’s revenue for the quarter was down .1% on a year-over-year basis. On average, sell-side analysts anticipate that Organon & Co. will post 4.14 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were issued a dividend of $0.28 per share. The ex-dividend date was Friday, August 16th. This represents a $1.12 dividend on an annualized basis and a yield of 6.21%. Organon & Co.’s payout ratio is currently 27.38%.

Analyst Upgrades and Downgrades

OGN has been the topic of several analyst reports. JPMorgan Chase & Co. cut Organon & Co. from a “neutral” rating to an “underweight” rating and increased their price objective for the company from $18.00 to $20.00 in a research note on Friday, September 6th. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $21.00.

Check Out Our Latest Analysis on Organon & Co.

About Organon & Co.

(Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Featured Articles

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNFree Report).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.